News – Page 1089 – Endpoints News

Imprimis spins out a new biotech focused on eye drugs; Alzheimer’s groups back PhII study at Amylyx

8 years ago

Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

8 years ago

In an update, Gilead spotlights top-line hits amid a mixed set of PhII data for its $600M NASH drug

8 years ago

Tiny hep B drug combo study touts potential of a ‘functional cure’ at little-known Replicor

8 years ago

Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM

8 years ago

Alexion bags a blockbuster new approval for its cash cow Soliris. Now what?

8 years ago

Going all in: Biogen commits an extra $500M to Alzheimer’s blockbuster hopeful aducanumab

8 years ago

AbbVie antes up $225M in cash to buy into the Alzheimer's platform at Alector

8 years ago

UK’s NICE will cover $700K cost of GSK’s gene therapy; Evoke shares spike on NDA plans

8 years ago

With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work

8 years ago

FDA adds fresh ‘breakthrough’ for Novartis' cancer combo Tafinlar and Mekinist

8 years ago

In a setback, Global Blood Therapeutics scraps IPF program as lead drug flounders in proof-of-concept trials

8 years ago

Takeda partner Finch joins forces with Crestovo, leaping into a mid-stage microbiome study

8 years ago

GSK grabs FDA OK for new shingles vaccine, which will now tackle a key Merck franchise

8 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

8 years ago

DBV shares are crushed — while rival Aimmune soars — after PhIII flop for peanut allergy med

8 years ago

Big Pharma R&D is exiting China, but leaving a legacy; China's biotech execs couldn’t be happier

8 years ago

Novartis partner Durect registers a PhIII pain drug flop, biotech’s shares crater

8 years ago

Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent fight?

8 years ago

Seattle's Universal Cells brings Astellas into its fold of off-the-shelf cell therapy partners

8 years ago

Biotech bad boy Martin Shkreli isn't getting his $5M in bail money back anytime soon

8 years ago

Peer Review: Eyeing a $350M venture fund, Nextech recruits Third Rock’s Jakob Loven for the team

8 years ago

FDA releases flurry of new, revised drug-specific guidance documents

8 years ago

Celgene’s $710M deal on mongersen implodes as Phase III Crohn's study flops

8 years ago

First page Previous page 1086 1087 108810891090 1091 1092 Next page Last page